Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Curis, Inc.
  6. News
  7. Summary
    CRIS   US2312692005

CURIS, INC.

(CRIS)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
0.7003 USD   +0.57%
09/22Curis Inc : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
09/22Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022
CI
09/19Curis Announces Date for the 2nd Annual VISTA Symposium
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

FDA Lifts Partial Hold on Curis' Lymphoma Study

08/18/2022 | 06:37am EDT

By Dean Seal


Curis Inc. said Thursday the U.S. Food and Drug Administration has lifted the partial clinical hold on its TakeAim Lymphoma study, a Phase 1/2 trial of emavusertib in patients with B-cell malignancies.

The cancer-focused biotechnology company announced the hold back in April, saying at the time that it was unexpected. The notification came from the FDA Division of Hematologic Malignancies 2, which regulates clinical studies in lymphoma.

The FDA lifted the hold after reviewing a comprehensive data package that Curis submitted, according to the company.

Chief Executive James Dentzer said the company is working to resume enrollment of new patients in the third quarter.

Shares soared 29.5% to $1.36 in premarket trading.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

08-18-22 0837ET

All news about CURIS, INC.
09/22Curis Inc : Change in Directors or Principal Officers, Financial Statements and Exhibits (..
AQ
09/22Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, ..
CI
09/19Curis Announces Date for the 2nd Annual VISTA Symposium
PR
09/07Curis to Present at Upcoming Healthcare Conferences in September
PR
08/31Curis, Inc. - FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of..
AQ
08/30Curis Says FDA Lifts Patient Enrollment Restriction in Monotherapy Phase of Cancer Trea..
MT
08/30Curis Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/30FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib i..
PR
08/30Curis, Inc. Announces That the U.S. Food and Drug Administration Has Notified Curis Tha..
CI
08/18Curis Says FDA Lifts Clinical Hold on Lymphoma Study of Emavusertib; Shares Climb Pre-B..
MT
More news
Analyst Recommendations on CURIS, INC.
More recommendations
Financials (USD)
Sales 2022 10,9 M - -
Net income 2022 -63,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,01x
Yield 2022 -
Capitalization 64,3 M 64,3 M -
Capi. / Sales 2022 5,91x
Capi. / Sales 2023 5,65x
Nbr of Employees 60
Free-Float 93,8%
Chart CURIS, INC.
Duration : Period :
Curis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CURIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,70 $
Average target price 14,00 $
Spread / Average Target 1 899%
EPS Revisions
Managers and Directors
James E. Dentzer President, Chief Executive Officer & Director
Diantha Duvall CFO, Treasurer & Chief Accounting Officer
Martyn D. Greenacre Chairman
Robert E. Martell Head-Research & Development
Mark W. Noel VP-Technology Management & Intellectual Property
Sector and Competitors
1st jan.Capi. (M$)
CURIS, INC.-85.37%64
MODERNA, INC.-51.87%46 823
IQVIA HOLDINGS INC.-35.18%34 705
LONZA GROUP AG-42.20%32 942
SEAGEN INC.-12.45%24 949
ALNYLAM PHARMACEUTICALS, INC.16.40%23 692